Chronic Kidney Disease Market Analysis

Diagnosis (Blood Test, Urine Test, Imaging Test, and Kidney Biopsy)

Blood tests segment is predicted to account for chronic kidney disease market share of more than 37% by the end of 2037, as they are crucial to the diagnosis of chronic kidney disease through important markers such as the eGFR and creatinine levels. These tests are quite needed in early detection and subsequently in further monitoring due to the fact that clinicians can assess kidney function and disease progression. In March 2022, Nova Biomedical introduced the Nova Max Pro Creatinine/eGFR Meter System to advance point-of-care kidney screenings. This will bridge the gap in the diagnosis of CKD, as blood tests remain an essential prerequisite. Growing utilization of blood testing is thus expected to strengthen the segment's leading position in the market, as health practitioners would seek greater support from these diagnostics in their quest for timely management of disease conditions.

Treatment (Drugs, Dialysis, and Kidney Transplant)

In chronic kidney disease market, drug segment is anticipated to account for revenue share of more than 45% by the end of 2037, due to increasing demand for drugs managing CKD and its comorbidities, like hypertension and diabetes. In September 2023, the FDA granted approval for Jardiance (empagliflozin) for chronic kidney disease treatment, marking a significant advancement in pharmaceutical options. New drugs being introduced further underscore the importance of the segment, as drugs remain an important factor in slowing the progress of CKD and alleviating its symptoms. Ongoing development of targeted therapies supports continued innovation within the drug segment, improving treatment efficacy while widening the choices of chronic kidney disease patients.

Our in-depth analysis of the global market includes the following segments: